Stallergenes Greer Ltd
http://stallergenesgreer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Stallergenes Greer Ltd
Novartis’s Peanut Allergy Setback Perks Up Rivals
Opportunity could knock for the smaller but more specialized players in the peanut allergy space now that Novartis has halted trials of its investigational IgE inhibitor ligelizumab.
Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts
Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.
Stallergenes Greer's Delisting To Focus Leadership On Facility Issues
The acquisition of the UK-headquartered leading allergy immunotherapy firm by its private majority shareholder is expected to remove the distraction of stock market listing obligations for management.
Stallergenes' Mite Allergy Results An Early Leaving Present For Retiring CEO
Positive Phase III data with its sublingual house dust allergy tablet heralds a likely increase in competition in the US allergy sector in the years to come and also provide an early leaving present for the company's retiring CEO.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alegro Pharma S.R.L.
- Greer Laboratories, Inc.
- Medic Savoure Limited
- Stallergenes Greer plc
- Stallergenes S.A.
- Stallergenes SAS
- Stallergenes S.A.S.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice